Neil Cashman, Director and Chief Scientific Officer of ProMIS Neurosciences Inc., filed a Form 4 on November 3, 2026, reporting a purchase of 10,000 common shares on November 2, 2026.

Key Highlights

  • Purchase transaction: Cashman acquired 10,000 common shares on November 2, 2026, at a price of $3.86 per share.
  • Direct ownership after transaction: Cashman directly holds 14,532 common shares following the reported purchase.
  • Indirect holdings: An additional 4,122 common shares are held indirectly by Research Capital Corporation, and 664 common shares are held indirectly by his spouse.
  • Roles: The filing identifies Cashman as both a Director and Chief Scientific Officer of ProMIS Neurosciences Inc.
  • Transaction code: The transaction is coded "P," indicating an open-market purchase.

Cashman's November 2026 Open-Market Purchase of ProMIS Common Shares

According to the Form 4 filed with the SEC on November 3, 2026, Neil Cashman purchased 10,000 common shares of ProMIS Neurosciences Inc. (NASDAQ:PMN) on November 2, 2026, at a price of $3.86 per share. The transaction is designated with code "P," reflecting an open-market purchase. The filing was signed by Max A. Milbury as Attorney in Fact for Neil Cashman.

Following the reported transaction, the filing discloses that Cashman directly holds 14,532 common shares. In addition, the filing reports two lines of indirect beneficial ownership: 4,122 common shares held by Research Capital Corporation and 664 common shares held by his spouse. No derivative securities transactions were reported in Table II of the filing.

The filing does not indicate that the transaction was made pursuant to a Rule 10b5-1(c) plan, as the corresponding checkbox on the form was not selected. The filing was made pursuant to Section 16(a) of the Securities Exchange Act of 1934, which requires officers, directors, and certain shareholders to report changes in their beneficial ownership of company securities.

What Was Disclosed

The filing reports a single open-market purchase of 10,000 ProMIS Neurosciences common shares by Director and Chief Scientific Officer Neil Cashman on November 2, 2026, at $3.86 per share, with resulting direct beneficial ownership of 14,532 shares.